Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
Jorge J. Castillo, Francesco Autore, Neil L. Berinstein, Andrew R. Branagan, Meletios A Dimopoulos, Carlos Fernández de Larrea, Simone Ferrero, Prashant Kapoor, Efstathios Kastritis, Jahanzaib Khwaja, Monique C. Minnema, Lugui Qiu, John F. Seymour, Josephine M. I. Vos, Christopher J. Patterson, Christian Buske, Jeffrey Matous, Steven P. Treon, M. Lia Palomba (2025). Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors. , 62(2), DOI: https://doi.org/10.1053/j.seminhematol.2025.04.004.
Article40 days agoReport of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
Christian Buske, Jorge J. Castillo, Jithma P. Abeykoon, Ranjana H. Advani, Suzanne O. Arulogun, Andrew R. Branagan, Xinxin Cao, Shirley D’Sa, Jian Hou, Prashant Kapoor, Efstathios Kastritis, Marie José Kersten, Véronique Leblond, Merav Leiba, Jeffrey Matous, Jonas Paludo, Lugui Qiu, Constantine S. Tam, Alessandra Tedeschi, Sheeba K. Thomas, Ibrahim Tohidi‐Esfahani, Marzia Varettoni, Josephine M. I. Vos, Ramón García‐Sánz, Jesús F. San Miguel, Meletios A Dimopoulos, Steven P. Treon, Judith Trotman (2023). Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. , 60(2), DOI: https://doi.org/10.1053/j.seminhematol.2023.03.005.
Article40 days agoP-423 Partial response or better at 6 months is not a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with zanubrutinib: a post hoc analysis of the ASPEN study
Jorge J. Castillo, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Stephen Opat, Andrew R. Branagan, Shayna Sarosiek, Gottfried von Keudell, Steven P. Treon, Heather Allewelt, Wai Yee Chan, Jingjing Schneider, Meletios A Dimopoulos (2023). P-423 Partial response or better at 6 months is not a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with zanubrutinib: a post hoc analysis of the ASPEN study. , 23, DOI: https://doi.org/10.1016/s2152-2650(23)02040-2.
Article40 days agoPRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRöM MACROGLOBULINEMIA WITH <i>MYD88</i> AND <i>CXCR4</i> MUTATIONS
Steven P. Treon, Christian Buske, Sheeba K. Thomas, Andrew R. Branagan, Meletios A Dimopoulos, J. J. Castillo, F. Garzon, Wenhao Tang, R. Ronan, Sean Seyffert, Vishvas Garg, S. Ali, Ana E Taveras, Anca Bădărău, Katarina Zmajkovicova, S. Maier, B. Maierhofer, J. Matouš (2021). PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRöM MACROGLOBULINEMIA WITH <i>MYD88</i> AND <i>CXCR4</i> MUTATIONS. , 39(S2), DOI: https://doi.org/10.1002/hon.86_2881.
Article40 days agoPreliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with <i>MYD88</i> and <i>CXCR4</i> Mutations
Steven P. Treon, Christian Buske, Sheeba K. Thomas, Jorge J. Castillo, Andrew R. Branagan, Meletios A Dimopoulos, Maria Gavriatopoulou, Diego Cadavid, Felix T. Garzon, Weihua Tang, Sean Seyffert, Varun Garg, Shariq Ali, Arthur G. Taveras, Kelly Chen, Jeffrey Matous (2021). Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with <i>MYD88</i> and <i>CXCR4</i> Mutations. , 138(Supplement 1), DOI: https://doi.org/10.1182/blood-2021-144706.
Article40 days ago